A Study to Determine the Optimal Dose of SCH 900222 for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (Study P05495)
| Status: | Archived |
|---|---|
| Conditions: | Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | October 2010 |
| End Date: | May 2013 |
Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous SCH 900222 in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Study P05495)
Each participant will be enrolled in the trial for approximately 72-76 weeks. Each
participant will receive assigned treatment at Weeks 0, 4, and 16 in Part I. At Week 16, the
dosage of treatment the patient is assigned to may be adjusted based on the Psoriasis Area
and Severity Index (PASI) 75 response (responder vs non-responder). Participants will
receive study medication once every 12 weeks during Part 2 (Weeks 16 to 52). Part 3 is an
observational period and each subject will continue to be monitored on a monthly basis
through Week 72. Subjects will not receive any study medication during Part 3.
We found this trial at
1
site
Click here to add this to my saved trials
